H. Lundbeck A/S
HLBBF
Other OTC7.29
USD
- -
- -
ISIN
DK0061804770
Return %
Stock
S&P500
1Y
27.00
26.84
3Y
43.79
77.03
5Y
54.12
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Charl van Zyl
- Full Time Employees
- 5,707
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Ottiliavej 9 Valby Denmark 2500
- IPO Date
- Jul 13, 2022
- Website
- lundbeck.com
- Similar Companies
- Business
- H. Lundbeck A/S, a Denmark-based international pharmaceutical company founded in 1915 and headquartered in Valby, Copenhagen, specializes in the research, development, manufacturing, marketing, and sale of innovative therapeutics for brain diseases including psychiatric and neurological disorders. The company operates in more than 50 countries with production facilities in Denmark, France, and Italy, research centers in Denmark and the USA, and products registered in over 100 countries worldwide. Its core portfolio encompasses treatments across multiple disease areas: for Parkinson's disease, Azilect (rasagiline); for alcohol dependence, Selincro (nalmefene); for Alzheimer's disease, Ebixa/Ebix/Abixa/Memantine Merz (memantine); for migraine, Vyepti (eptinezumab); for epilepsy, Sabril (vigabatrin), Onfi/Frisium (clobazam); for depression and anxiety, Rexulti/Rxulti (brexpiprazole), Brintellix/Trintellix/Fonksera/Vortioson/Vurtuoso (vortioxetine), Cipralex/Lexapro/Sipralexa/Seroplex/Entact/Lepax/Premalex/Prilect/Esipram/Esertia/Rhea Escitalopram (escitalopram oxalate), Cipramil/Seropram/Cipram/Sepram/Celexa/Elopram/Prisdal (citalopram), Deanxit (flupentixol + melitracene), Noritren/Nortrilen/Sensaval (nortriptyline), and Saroten/Sarotex/Redomex/Sarotena (amitriptyline); for psychosis, Rexulti/Rxulti (brexpiprazole), Abilify Maintena (aripiprazole), Serdolect (sertindole), Cisordinol/Clopixol/Ciatyl-Z (zuclopenthixol), Cisordinol Depot/Clopixol Depot/Ciatyl-Z Depot (zuclopenthixol decanoate), Fluanxol Depot/Depixol/Fluanxol LP/Fluanxol Retard (cis(Z)-flupentixol decanoate), Fluanxol/Fluanxol Mite/Depixol (flupentixol), Truxal (chlorprothixene), and Cisordinol-Acutard/Clopixol-Acutard/Clopixol-Acuphase/Ciatyl-Z-Acuphase (zuclopenthixol acetate); and for other indications, Northera (droxidopa). In recent developments, Lundbeck completed the acquisition of Longboard Pharmaceuticals in 2024 for approximately $2.6 billion, significantly enhancing its neuroscience pipeline; announced a restructuring of commercial operations impacting over 600 international employees to adopt a partner-model for global markets; and raised its full-year 2025 financial guidance for revenue and adjusted EBITDA growth at constant exchange rates, supported by strong year-to-date revenue increases driven by key brands like Vyepti. The Lundbeck Foundation maintains majority ownership of approximately 69%.
H. Lundbeck A/S (HLBBF) Shareholder/Analyst Call Transcript
H. Lundbeck A/S (HLBBF) Q4 2025 Earnings Call Transcript
H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal
H. Lundbeck A/S (HLBBF) Q3 2025 Earnings Call Transcript
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan